Please assess the completion status of the following clinical trial:

Trial Title: Bupivacaine for Benign Headache in the ED

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Age 18-65 years old~2. Diagnosis of benign or primary headache~Exclusion Criteria:~1. Hypersensitivity or allergy to bupivacaine (amide anesthetics) or prochlorperazine or other drugs in the same class, dopaminergic blockers.~2. Overlying signs of infection at site of injection (Erythema, purulence, open skin)~3. Neck pathology ( History of surgery to the cervical spine, History of surgical hardware in place, Documented disc abnormality, History of vertebral artery or carotid artery dissection, Torticollis)~4. Intracranial abnormality/pathology (Tumor, Hemorrhage, Concussion or post concussive syndrome)~5. History of increased intracranial pressure (ICP)~6. A known history of extrapyramidal symptoms, dystonia, parkinsonism, tardive dyskinesia or neuroleptic malignant syndrome~7. Known pregnancy~8. Narcotic seeking patients as determined by the treating physician with optional assistance from medical record review and North Carolina Drug Database

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- standard care (Type: ACTIVE_COMPARATOR): intravenous Prochlorperazine
- treatment (Type: EXPERIMENTAL): 0.5% bupivacaine

Based on this trial design, predict the completion outcome and termination type (if applicable).